Northwestern Finds FDA-Approved Montelukast Boosts Immunotherapy in 5 Cancer Models
Updated
Updated · Good News Network · May 24
Northwestern Finds FDA-Approved Montelukast Boosts Immunotherapy in 5 Cancer Models
2 articles · Updated · Good News Network · May 24
Nature Cancer published Northwestern data showing montelukast and other CysLTR1 blockers slowed tumor growth, improved survival and restored immunotherapy response in mouse models of five aggressive cancers.
CysLTR1 appears to be the switch tumors use to turn neutrophils into immune-suppressing cells; blocking it reprogrammed those white blood cells to support anti-tumor attack instead of helping cancers evade treatment.
Human immune-cell tests, tumor samples and large patient datasets backed the mechanism, with higher CysLTR1 activity linked to worse survival and weaker immunotherapy responses across multiple cancers.
Montelukast’s existing FDA approval could speed clinical testing, with researchers targeting hard-to-treat tumors such as triple-negative breast cancer where immunotherapy often fails.
If a cheap asthma pill can fight tumors, what other cancer cures are hiding in plain sight on pharmacy shelves?
Can an allergy drug with a serious psychiatric risk warning be safely repurposed to fight aggressive cancer?
2026 Breakthrough: Montelukast Reprograms Immune Cells to Enhance Cancer Immunotherapy
Overview
A major breakthrough from Northwestern University shows that montelukast, a widely used and safe asthma drug, can reprogram immune cells in the tumor microenvironment to boost cancer immunotherapy. This discovery, published in May 2026, is especially important for aggressive cancers like triple-negative breast cancer and melanoma. By turning off a key switch in immune cells, montelukast helps the body’s own defenses fight cancer more effectively. Its established safety and broad use mean it could quickly move into clinical trials, offering new hope for patients with hard-to-treat cancers.